Literature DB >> 15242771

Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway.

Laura M DeBusk1, Dennis E Hallahan, Pengnian Charles Lin.   

Abstract

Tie2 and VEGF receptors (VEGFRs) are tyrosine kinases that play essential roles in angiogenesis. Activation of both receptors leads to the activation of Akt, an important mediator of cell survival and cell motility. In this study, we compared the role of Akt in Tie2-mediated versus VEGF-mediated endothelial cell (EC) survival and EC sprouting. Our data show that Akt is required and sufficient to mediate Ang1-induced EC survival in response to growth factor depletion. Blocking Akt function abolishes angiopoietin 1 (Ang1), a ligand for Tie2, mediated EC survival, and activating Akt rescues a Tie2 blockade-induced EC apoptosis. In contrast, activating Akt rescues EC apoptosis induced by a VEGF blockade, but interestingly, blocking Akt function has no effects on VEGF-induced EC survival, demonstrating that Akt is sufficient but not required for VEGF-mediated EC survival. In addition, we show that both Ang1 and VEGF induce EC sprouting in a three-dimensional collagen gel, which depends on the activation of Akt. Blocking Akt action inhibited EC sprouting induced by Ang1 or VEGF. Therefore, the data show that Akt is the primary mediator of Ang1-induced EC survival while multiple pathways are involved downstream of VEGF responsible for EC survival. However, Akt is required and sufficient to mediate the EC sprouting induced by both Ang1 and VEGF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15242771     DOI: 10.1016/j.yexcr.2004.04.013

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  43 in total

Review 1.  The vasculature in rheumatoid arthritis: cause or consequence?

Authors:  Ewa M Paleolog
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

Review 2.  Targeting microvasculature for neuroprotection after SCI.

Authors:  Janelle M Fassbender; Scott R Whittemore; Theo Hagg
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

3.  Angiopoietin-2: marker or mediator of angiogenesis in continuous-flow left ventricular assist device patients?

Authors:  Lauren K Truby; Veli K Topkara
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

4.  Signaling and functions of angiopoietin-1 in vascular protection.

Authors:  Nicholas P J Brindle; Pipsa Saharinen; Kari Alitalo
Journal:  Circ Res       Date:  2006-04-28       Impact factor: 17.367

Review 5.  Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system.

Authors:  Hellmut G Augustin; Gou Young Koh; Gavin Thurston; Kari Alitalo
Journal:  Nat Rev Mol Cell Biol       Date:  2009-03       Impact factor: 94.444

Review 6.  Strategies to promote donor cell survival: combining preconditioning approach with stem cell transplantation.

Authors:  Husnain Kh Haider; Muhammad Ashraf
Journal:  J Mol Cell Cardiol       Date:  2008-05-10       Impact factor: 5.000

7.  Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators.

Authors:  S E Wang; Y Yu; T L Criswell; L M Debusk; P C Lin; R Zent; D H Johnson; X Ren; C L Arteaga
Journal:  Oncogene       Date:  2010-04-12       Impact factor: 9.867

8.  Interleukin-32beta propagates vascular inflammation and exacerbates sepsis in a mouse model.

Authors:  Hanako Kobayashi; Jianhua Huang; Fei Ye; Yu Shyr; Timothy S Blackwell; P Charles Lin
Journal:  PLoS One       Date:  2010-03-05       Impact factor: 3.240

9.  Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy.

Authors:  Jeff H Tsai; William M F Lee
Journal:  Mol Cancer Res       Date:  2009-03-10       Impact factor: 5.852

Review 10.  Angiopoietin-1 and Angiopoietin-2 in metabolic disorders: therapeutic strategies to restore the highs and lows of angiogenesis in diabetes.

Authors:  A M Isidori; M A Venneri; D Fiore
Journal:  J Endocrinol Invest       Date:  2016-06-25       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.